Drug Database
HE

Hep A-Vi (ViATIM / ViVAXIM)

✓ Approved

Sanofi S.A · Vaccine · Vaccine

What is Hep A-Vi?

Hep A-Vi is a vaccine developed by Sanofi S.A. It is approved for therapeutic indications via injectable (others) or intramuscular (im) injection.

Drug Profile

Brand NamesViATIM, ViVAXIM
CompanySanofi S.A
Drug ClassVaccine, Large Molecules
RouteInjectable (Others), Intramuscular (IM) Injection
StatusApproved
Sources: ClinicalTrials.gov, Sanofi S.A

Therapeutic Indications

Hep A-Vi is developed for 2 unique indications across 2 therapeutic areas.

Therapeutic AreaConditionPhase
Infections and infestationsTyphoid fever✓ Approved
Surgical and medical proceduresAntiviral prophylaxis✓ Approved

Related Research Articles

PubMedEuropean radiology2026-10-15

Impact of VI-RADS quality score on VI-RADS diagnostic performance for muscle invasion: the role of tumor size and reader experience.

Joo Yohan Y, Cho Seong Woo SW, Tse Justin Ruey JR, Yoon Jongjin J et al.

To evaluate the inter-reader agreement of the Vesical Imaging Reporting and Data System (VI-RADS) quality scoring system and to assess its impact on the diagnostic performance for detecting muscle invasion. This retrospective study included 587 patients who underwent multiparametric bladder MRI before surgery. Three radiologists (two specialists and one non-genitourinary radiologist) independently assessed VI-RADS category and quality scores. Inter-reader agreement was evaluated using weighted kappa statistics. Associations between image quality, VI-RADS categorization, and tumor characteristics were analyzed using multivariable models. Diagnostic performance for muscle invasion was assessed at predefined VI-RADS thresholds and compared across quality groups and tumor size subgroups. A total of 7/587 (1.2%), 284/587 (48.4%), and 296/587 (50.4%) scans were VI-RADS quality score 0, 1, and 2, respectively. Inter-reader agreement for the final quality score was substantial (k = 0.628-0.702). Higher VI-RADS quality scores were associated with increased T2-weighted image VI-RADS scores (odds ratio [OR], 2.95; 95% confidence interval, 1.17-7.43; p = 0.021). In tumors < 3 cm, particularly for the less experienced reader, higher image quality was associated with increased positive predictive value (PPV) and accuracy at the VI-RADS ≥ 3 threshold (PPV: 51.0% vs 22.7%, p = 0.004; accuracy: 81.6% vs 71.7%, p = 0.023). No significant differences in diagnostic performance were observed across VI-RADS thresholds in tumors ≥ 3 cm. The VI-RADS quality scoring system demonstrated good inter-reader agreement. Optimal image quality improved diagnostic performance in small tumors and for the less experienced reader; however, because only one less experienced reader was included, this finding requires external validation. Question Does image quality, assessed by the VI-RADS quality score, influence diagnostic performance of VI-RADS for detecting muscle invasion in bladder cancer? Findings Higher image quality improved PPV and accuracy of VI-RADS, particularly in tumors < 3 cm and for the less experienced reader, while having limited impact in larger tumors. Clinical relevance Ensuring optimal MRI image quality enhances the reliability of VI-RADS interpretation, particularly in small tumors and non-specialized settings, and supports standardized imaging as a prerequisite for accurate bladder cancer staging.

PMID 42875622
Read full article →
PubMedJournal of the American Geriatrics Society2026-10-15

Vision Impairment, Vision Correction, and Dementia Risk in Mild Cognitive Impairment.

Tang Huilin H, Wolk David A DA, Ying Gui-Shuang GS, Wang Tiansheng T et al.

Among individuals with mild cognitive impairment, no vision impairment (VI) and corrected VI were associated with a lower risk of dementia than uncorrected VI, particularly among those aged < 75 years.

PMID 42875826
Read full article →
PubMedSurgical and radiologic anatomy : SRA2026-10-15

Three-dimensional anatomical classification and machine learning prediction of the P6a-right hepatic vein relationship: surgical implications for laparoscopic right anterior sectionectomy.

Li Haoming H, Liu Chengli C, Zhang Jingchen J, Huang Hao H et al.

The spatial relationship between the ventral branch of segment VI portal vein (P6a) and the right hepatic vein (RHV) significantly influences the anatomical complexity of the right hepatic fissure and the surgical outcomes of laparoscopic right anterior sectionectomy (LRAS). The ventral-P6a variant is often associated with higher surgical risks, yet preoperative prediction remains challenging. This retrospective study included 100 patients who underwent triple-phase enhanced CT of the upper abdomen. Based on three-dimensional reconstructions, P6a was classified as dorsal or ventral relative to the RHV according to its anatomical relationship. Five machine learning models-logistic regression, random forest, K-nearest neighbors, support vector machine, and XGBoost-were employed to predict P6a classification using anatomical angular and linear measurements. Model performance was evaluated using the area under the receiver operating characteristic curve (AUC) and the F1-score, and the SHAP method was applied for feature interpretation. Among the 100 patients, 59% were classified as dorsal-P6a and 41% as ventral-P6a. The ventral-P6a group exhibited a significantly smaller angle between the anterior and posterior portal branches (82.27° vs. 98.02°, P = 0.003), a higher proportion with a distance of less than 5 mm from the P6a origin to the posterior branch origin (37% vs. 10%, P = 0.001), and a larger RHV-inferior vena cava angle (52.23° vs. 43.97°, P = 0.013). The logistic regression model demonstrated the best performance in the test set (F1-score = 0.741) with minimal overfitting. The most important predictive features included the angle between the anterior and posterior portal branches, the angle of the right hepatic fissure plane, and the diameter of P6a. SHAP analysis validated the interpretability of the model. A machine learning model based on three-dimensional imaging anatomical features can effectively predict the spatial classification of P6a relative to the RHV. The interpretable logistic regression model identifies key anatomical risk factors, providing a basis for preoperative risk assessment and surgical planning in LRAS, particularly for optimizing surgical strategies in high-risk patients with the ventral-P6a variant.

PMID 42875673
Read full article →
PubMedAngewandte Chemie (International ed. in English)2026-10-15

Mechanophotochemistry: Lighting up EDA Complexes in the Solid State.

Srivastawa Aniket Kumar AK, Zysman-Colman Eli E

Solvent arguably constitutes the single largest waste stream in synthesis. Mechanophotocatalysis, a synergistic union of mechanochemistry and photocatalysis, offers a solution to significantly reduce solvent use in photochemistry. Here, we show how photochemical reactions in the solid state can be driven by visible light using in situ formed electron donor-acceptor (EDA) complexes in air, obviating the need for an external photocatalyst. Under the optimized conditions, only 2-4 equiv. of solvent is used as a liquid-assisted grinding (LAG) agent, thus significantly reducing solvent use. We demonstrate EDA mechanophotochemistry across five reactions: a Giese reaction; a C─S cross-coupling reaction; a phosphorylation reaction; a sulfonylation reaction; and a Povarov reaction. While the first four proceeded readily and competitively with the solution-state EDA photochemical reaction, the latter one, requiring O2 as a terminal oxidant, does not. In investigating the sulfonylation reaction we further identify the first example of a photomechanoredox reaction in which the stainless-steel milling ball directly participates in the reaction, revealing the milling medium as a previously unrecognized reactivity parameter. Together, these results establish visible light-promoted mechanophotochemistry as a solvent-minimized and viable alternative to solution-state photochemical reactions.

PMID 42875875
Read full article →
PubMedAtherosclerosis plus2026-10-15

Lipoprotein(a) and early LDL-cholesterol target attainment after a first acute coronary syndrome: a real-world cohort study.

Riera-Molist Núria N, Puigoriol Juvanteny Emma E, Swedzky Federico F, Goutan-Roura Ester E et al.

Despite intensive lipid-lowering therapy, early attainment of the guideline-recommended LDL-cholesterol (LDL-C) target after acute coronary syndrome (ACS) remains suboptimal. Baseline factors associated with early LDL-C target attainment remain incompletely characterized, particularly the role of lipoprotein(a) [Lp(a)]. We aimed to assess early LDL-C target attainment after a first ACS and identify baseline factors associated with target attainment, with a particular focus on Lp(a). We conducted a retrospective cohort study of consecutive hospitalized adults with a first ACS undergoing percutaneous coronary intervention between January 2025 and April 2026. The primary endpoint was attainment of the guideline-recommended LDL-C target at early follow-up, defined as LDL-C < 55 mg/dL and a ≥ 50% reduction from baseline. Associations between clinical variables and LDL-C target attainment were assessed using multivariable logistic regression. Eighty-two patients were included; 70.7% were male and 37.2% had elevated Lp(a) levels. At a median follow-up of 5 weeks (IQR, 4-6), 31.7% attained the LDL-C target despite prescription of high-intensity statin therapy at discharge. In the multivariable model, low Lp(a) (OR 8.72; 95% CI 2.04-37.33), current smoking (OR 5.29; 95% CI 1.42-19.69), and ezetimibe use in addition to high-intensity statin therapy at discharge (OR 5.28; 95% CI 1.31-21.32) were associated with LDL-C target attainment. Early LDL-C target attainment after a first ACS remained limited despite routine prescription of high-intensity statin therapy. Elevated Lp(a) was associated with a lower likelihood of attaining the LDL-C target. Prospective studies are needed to confirm these findings.

PMID 42876442
Read full article →
PubMedEmergency radiology2026-10-15

Ultra-high-resolution photon-counting CT argues against a suspected bilateral carotid web: a case report.

Ben-David Eliel E, Bogot Naama R NR, Berrebi Yehonathan Y, Tetro Tamar T et al.

Carotid web is diagnosed almost entirely from a shelf-like filling defect at CT angiography (CTA), yet the posterolateral carotid bulb at which webs arise is also a site of flow separation in which blood of differing contrast density mixes. We describe a bilateral web-like appearance at this site and determine whether it arose from reconstruction or acquisition. A 75-year-old woman with a right-hemispheric transient ischemic attack had three carotid CTA examinations: a dual-energy energy-integrating-detector CT (EID-CT) angiogram five months before presentation, a stroke-protocol photon-counting-detector CT (PCD-CT) angiogram at presentation, and a dedicated ultra-high-resolution PCD-CT angiogram three days later. Each photon-counting acquisition was additionally reconstructed with other section thicknesses, kernels or energies, and attenuation across the appearance was measured. A bilateral shelf-like filling defect closely simulating a carotid web was present on the EID-CT and presenting PCD-CTF angiograms but absent on the ultra-high-resolution study. The tested reconstructions neither abolished the appearance nor elicited it. The ultra-high-resolution study was acquired 16.6 s after the end of injection at less than half the table speed, versus 10.3 s on the presenting study. Attenuation at the corresponding position measured 62%, 54% and 87% of luminal attenuation, respectively. No carotid intervention was undertaken. An acquisition-dependent bilateral carotid bulb pseudolesion can mimic a carotid web on both EID-CT and PCD-CT angiography and is most consistent with flow-related mixing of blood of differing contrast density. A slower repeat acquisition of the carotid bulb with a few seconds more delay may prevent unnecessary revascularization.

PMID 42875681
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about Hep A-Vi